Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025

Set out below is the key unaudited financial information of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("**Endovastec**") for the three months ended 31 March 2025. Endovastec is owned as to 40.32% by the Group and its results are consolidated with the financial statements of the Company. The shares of Endovastec are listed on the science and technology innovation board of the Shanghai Stock Exchange.

	For the three months ended 31 March 2025	For the three months ended 31 March 2024	Change
	RMB'000	*RMB'000*	*%*
Revenue	**332,189.4**	358,081.4	-7.23%
Profit	**150,865.6**	216,760.7	-30.40%
Net profit attributable to equity owners of Endovastec	**129,636.9**	184,296.1	-29.66%

	As of 31 March 2025	As of 31 December 2024	Change
	RMB'000	*RMB'000*	*%*
Total assets	**4,464,876.8**	4,291,597.5	4.04%
Total equity attributable to equity owners of Endovastec	**3,845,735.7**	3,791,843.0	1.42%

Shareholders and investors are reminded that the financial information of Endovastec above was prepared in accordance with PRC accounting standards and is limited solely to the operation of Endovastec and is unrelated to the other subsidiaries of the Group. Such information is unaudited, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 29 April 2025

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*